Jeffrey Low

Investor focused at the intersection of life sciences, healthcare, and technology. Jeffrey invests across therapeutics, AI drug discovery, life‑sciences technology, and digital health—partnering with teams building therapeutics, care‑delivery models, and the software infrastructure for health. His most recent move to Averin positions him to lead West Coast investments in these areas. averincapital+2

Bridges medicine and business: Jeffrey combines clinical training (MD from Yale) with business education (MBA from Harvard Business School) and a molecular/biology undergraduate background (Harvard AB). That combination underpins his diligence in evaluating biologics, diagnostics, and AI-enabled life‑sciences platforms. jeffreylow+1

Experienced in both early-stage and growth investing. He worked as a partner on a16z's Bio Fund—supporting a broad portfolio across therapeutics, AI drug discovery, and digital health—and later led Novo Growth's life‑sciences strategy, where he supported large financings and public market transitions (notably working with Exscientia and other growth-stage companies). a16z+2

Active at both early discovery and corporate growth stages: he participates as a scout for Sequoia Capital (sourcing early AI+life‑sciences opportunities) while also leading larger growth-stage diligence and board work—demonstrating comfort across the investment lifecycle from pre‑seed/seed discovery to late growth and public-market transitions. jeffreylow+1